Want to see SIGY full AI Analyst Report?
Top Page
Sigyn Therapeutics
(OTC:SIGY)
Select Model
Select Model
Rating:26Underperform
Price Target:―
Action:N/A
Date:11/13/24
The overall score reflects significant financial challenges, including persistent net losses, high leverage, and no revenue growth. Technical indicators show mixed signals, with potential short-term upward momentum but risk of being overbought. The valuation is concerning with a negative P/E ratio, suggesting the stock is not a value play. The lack of clear communication in the earnings call adds to the uncertainty. Overall, the stock presents high risk with limited visibility into future improvements.
Positive Factors
Innovative Technology
The company's proprietary blood purification technology addresses critical medical needs, offering potential for strong market demand and strategic partnerships in healthcare.
Negative Factors
Financial Instability
Persistent financial difficulties indicate challenges in achieving profitability and sustainability, posing risks to long-term operational viability and investor confidence.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Technology
The company's proprietary blood purification technology addresses critical medical needs, offering potential for strong market demand and strategic partnerships in healthcare.
Read all positive factors
Sigyn Therapeutics (SIGY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$46.56K
Dividend YieldN/A
Average Volume (3M)17.65K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue GrowthN/A
EPS Growth12.05%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.09
Shares Outstanding1,605,377
10 Day Avg. Volume15,352
30 Day Avg. Volume17,647
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-0.43
Price to Sales (P/S)0.00
P/FCF Ratio-3.23
Enterprise Value/Market Cap59.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.8
Revenue Forecast (FY)N/A
Sigyn Therapeutics Business Overview & Revenue Model
Company Description
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing dru...
How the Company Makes Money
Sigyn Therapeutics generates revenue primarily through the commercialization of its blood purification technology, which targets hospitals and healthcare providers treating patients with severe inflammatory conditions. The company may also engage ...
Sigyn Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.36K | -5.61K | -8.86K | -10.45K | ― |
| EBITDA | -2.59M | -1.78M | -2.52M | -2.45M | -2.14M | -2.53M |
| Net Income | -3.62M | -3.36M | -3.34M | -4.15M | -3.71M | -3.40M |
Balance Sheet | ||||||
| Total Assets | 50.27K | 107.52K | 213.72K | 321.81K | 332.88K | 710.26K |
| Cash, Cash Equivalents and Short-Term Investments | 265.00 | 20.33K | 12.14K | 11.69K | 8.36K | 340.96K |
| Total Debt | 3.18M | 3.06M | 2.19M | 2.40M | 1.88M | 980.01K |
| Total Liabilities | 7.32M | 6.55M | 4.67M | 3.73M | 2.24M | 974.84K |
| Stockholders Equity | -7.27M | -6.44M | -4.46M | -3.41M | -1.90M | -264.58K |
Cash Flow | ||||||
| Free Cash Flow | -654.39K | -852.28K | -872.44K | -1.38M | -1.83M | -1.80M |
| Operating Cash Flow | -654.39K | -852.27K | -872.44K | -1.38M | -1.83M | -1.77M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -860.00 | -29.26K |
| Financing Cash Flow | 641.76K | 860.46K | 872.89K | 1.39M | 1.50M | 2.06M |
Sigyn Therapeutics Technical Analysis
Neutral
0.03
Price Trends
0.03
Negative
0.04
Negative
0.44
Negative
Market Momentum
>-0.01
Negative
50.05
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGY, the sentiment is Neutral. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.44, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SIGY.
Sigyn Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.87M | -0.28 | -166.67% | ― | ― | 88.77% | |
42 Neutral | $11.61M | -0.38 | -93.49% | ― | ― | 94.38% | |
42 Neutral | $4.02M | -0.14 | -100.19% | ― | ― | 95.51% | |
42 Neutral | $10.88M | -0.14 | -205.45% | ― | ― | 78.16% | |
41 Neutral | $162.56M | -0.18 | -302.75% | ― | ― | 81.43% | |
26 Underperform | $46.56K | -0.01 | 57.73% | ― | ― | 12.05% |
* Healthcare Sector Average
SIGY
Sigyn Therapeutics
0.03
-4.32
-99.33%
TOVX
Theriva Biologics
0.25
-0.13
-34.63%
INDP
Indaptus Therapeutics
1.22
-1.69
-58.08%
REVB
Revelation Biosciences
1.01
-10.27
-91.05%
DRMA
Dermata Therapeutics
1.21
-4.05
-77.00%
AZTR
Azitra Inc
0.18
-0.62
-77.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.